治疗相关性与新发核心结合因子急性髓系白血病的比较:一项骨髓病理学组研究
这项多机构回顾性研究分析了351例核心结合因子急性髓系白血病(CBF-AML)患者,其中治疗相关69例、新发282例。治疗相关患者年龄更大、白细胞计数更低,虽接受相似治疗但总生存期短于新发患者(中位69个月 vs 190个月,P=.038)。多因素分析显示年龄较大和无任何继发性细胞遗传学异常是总生存期缩短的显著预测因素。
要点
- 治疗相关CBF-AML患者总生存期短于新发患者(中位69 vs 190个月,P=.038)。
- 继发性细胞遗传学异常者总生存期长于无异常者(中位190 vs 87个月,P=.021)。
- N/KRAS突变在t(8;21) AML患者中与更长总生存期相关(P=.001)。
核心结论
- 治疗相关与新发CBF-AML患者虽共享许多特征,但治疗相关患者临床结局差于新发患者。
研究设计与样本
- 多机构回顾性研究,纳入351例核心结合因子急性髓系白血病(CBF-AML)患者,其中治疗相关69例、新发282例。
- 对165例进行了靶向基因测序。
主要发现
- 治疗相关CBF-AML患者年龄更大、白细胞计数更低、血红蛋白略高于新发患者。
- 继发性细胞遗传学异常在新发患者中比治疗相关患者更常见(57.1% vs 41.1%,P=.026)。
- 有继发性细胞遗传学异常者总生存期长于无异常者(中位190 vs 87个月,P=.021);8三体、22三体和X或Y染色体缺失与更长总生存期相关。
- 165例靶向基因测序中75.7%检出致病突变,新发患者突变频率高于治疗相关患者(P=.013);突变见于N/KRAS(37.0%)、FLT3(27.8%)、KIT(17.2%)、TET2(4.9%)和ASXL1(3.9%)。
- TET2突变与更短总生存期相关(P=.012),而N/KRAS突变在t(8;21) AML患者中与更长总生存期相关(P=.001);KIT突变在本队列中未显示预后意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This multi-institutional study retrospectively evaluated clinicopathologic and genetic characteristics in 351 patients with core-binding-factor acute myeloid leukemia (CBF-AML), comprising 69 therapy-related (t-CBF-AML) and 282 de novo cases. The T-CBF-AML patients were older, had lower WBC counts, and slightly higher hemoglobin than patients with de novo disease. Secondary cytogenetic abnormalities were more frequent in patients with de novo disease than t-CBF-AML (57.1% vs 41.1%, P = .026). Patients with secondary cytogenetic abnormalities had longer overall survival (OS) than those without abnormalities (median 190 vs 87 months, P = .021); trisomy 8, trisomy 22, and loss of the X or Y chromosome were associated with longer OS. In the 165 cases performed of targeted gene sequencing, pathogenic mutations were detected in 75.7% of cases, and were more frequent in de novo than in therapy-related disease (P = .013). Mutations were found in N/KRAS (37.0%), FLT3 (27.8%), KIT (17.2%), TET2 (4.9%), and ASXL1 (3.9%). The TET2 mutations were associated with shorter OS (P = .012) while N/KRAS mutation was associated with longer OS in t(8;21) AML patients (P = .001). The KIT mutation did not show prognostic significance in this cohort. Although they received similar therapy, t-CBF-AML patients had shorter OS than de novo patients (median 69 vs 190 months, P = .038). In multivariate analysis of all patients, older age and absence of any secondary cytogenetic abnormalities were significant predictors of shorter OS. Among the t-CBF-AML subset, age and hemoglobin were significant on multivariate analysis. This study demonstrated that although de novo and t-CBF-AML patients share many features, t-CBF-AML patients have worse clinical outcome than de novo patients.
引用
- Rogers HJ, Wang X, Xie Y, et al. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Am J Hematol. 2020. PMID: 32249963. doi:10.1002/ajh.25814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。